Veerhealth Care Limited

Veerhealth Care Ltd's Preferential Issue Committee has approved the allotment of 1,00,00,000 Fully Convertible Warrants to 10 individuals, comprising both promoters and non-promoters. Each warrant carries the right to subscribe to one equity share at an issue price of ₹20.25 per warrant. The meeting was held on July 2, 2026, and concluded within an hour. This preferential allotment is a significant corporate action aimed at raising capital or strengthening the company's financial structure.

Veerhealth Care Ltd has announced the closure of its trading window for designated persons and their immediate relatives. The window will remain shut from July 1, 2026, until 48 hours after the declaration of the company's audited financial results for the year ending June 30, 2026. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct, aimed at preventing insider trading.

Veerhealth Care Limited has announced receiving a repeat order worth ₹3.60 Crores from a leading Indian FMCG company for its skincare products. This order is a testament to the client's satisfaction and the quality of Veerhealth Care's offerings. The company specializes in pure vegetarian toothpaste and Ayurvedic medicines under the Ayuveer brand. The order is expected to be executed within 45 days. The buyer is part of a prominent, 125-year-old business group operating in the personal and household care segment, with both domestic and international reach. Veerhealth Care also highlighted its US FDA plant clearance and expressed optimism about exceeding its FY27 revenue targets of ₹70-75 Crores, aiming for ₹100 Crores in revenue with 10% PAT within 24 months.

Veerhealth Care Ltd. has announced a significant new order worth ₹3.6 Crores (360 Lakhs) from a prominent Indian FMCG company for skincare products. The order is to be executed within 45 days. This contract is expected to contribute to the company's turnover and future growth. The company confirmed no promoter or group company interest in the awarding entity and that the transaction is not a related party transaction.

Veerhealth Care Limited reported a significant 86.08% year-over-year growth in total revenues for FY26, reaching ₹33.29 Crore. EBITDA also saw a substantial increase of 82.68% YoY to ₹3.27 Crore. The company's net profit grew by 38.46% YoY to ₹0.54 Crore. The Q4 FY26 profit was impacted by a Forex Loss of ₹0.31 Crore and a ₹0.49 Crore provision for Deferred Tax, which are not expected to recur in FY27. The company highlighted the positive impact of the India-EU Trade Deal 2026 on Ayurveda exports and is working on scaling manufacturing for medical devices in the U.S. market, with ongoing discussions for oral care exports to Russia. Key milestones include significant orders from the USA, domestic markets, and leading FMCG companies, along with onboarding Ayuveer products on Myntra and commencing production at a new facility with in-house molding. Veerhealth Care also secured USFDA plant clearance, positioning it uniquely among small-cap companies. The company projects revenues of ₹70-75 Crores in FY27 and aims for ₹100 Crores within 24 months.

Veerhealth Care Ltd has announced its audited financial results for the year ended March 31, 2026. The company's revenue from operations stood at ₹3248.45 lakhs, compared to ₹1686.66 lakhs in the previous year. However, the company reported a loss of ₹35.37 lakhs for the period, against a profit of ₹39.15 lakhs in the previous year. The Board of Directors did not recommend any dividend on equity shares for the financial year ended March 31, 2026.

Veerhealth Care Ltd has appointed M/s. Vivek P. Joisar & Co., Chartered Accountants, as its internal auditor for the financial year 2026-2027. The appointment was approved by the Board of Directors at their meeting on May 30, 2026. Vivek P. Joisar & Co. was formed in 2017 and has experience in finance, auditing, taxation, and transaction advisory services.

Veerhealth Care Ltd has announced its audited financial results for the quarter and year ended March 31, 2026. The company's revenue from operations for the year stood at ₹3248.45 lakhs, with a net profit of ₹54.40 lakhs. The Board of Directors did not recommend any dividend on equity shares for the financial year ended March 31, 2026. The financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 30, 2026.

Veerhealth Care Ltd has scheduled a Board of Directors meeting on May 30, 2026, to consider and approve the audited financial results for the quarter and financial year ended March 31, 2026, and to consider recommendation of dividend, if any. The trading window, which was closed from April 1, 2026, will reopen on June 2, 2026.

Veerhealth Care Ltd has received a repeat order worth ₹2.45 crores from a leading Indian FMCG company for personal care products. The order, for face care products, is to be executed within 45 days. The buyer operates in domestic and international markets within the 'personal and household care' segment and is part of a 125-year-old business group. Veerhealth Care anticipates revenues of ₹50-70 crores with a PAT of 7-10% in FY 2026-27 and expects to reach ₹100 crores revenue with 10% PAT in the next 24 months.